Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Abstract

Abstract Abstract 2767 Poster Board II-743 Introduction: The availability of effective disease-modifying therapies for patients with MDS, means standardised criteria for diagnosis, classification, prognostication and evaluation of treatment response are increasingly important. This has been achieved in part by the 2008 WHO classification. FC is now included as a co-criterion for diagnosis in the MDS consensus statement (Leuk Res 2007). Our aim was to explore the role of FC as a sensitive and objective tool for assessment of therapeutic efficacy. Patients and Met..